Accumulation of clots causes some of the most severe symptoms of sickle cell disease, including strokes, kidney failure, ...

A new review and policy statement underscore the inaccuracy of sickle cell trait as a cause of death on autopsies.

News 8 is once again honoring Black history by looking at health care and the racial disparities many report facing.

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

In addition to the prolonged pain and suffering endured by sickle cell patients, a Washington University School of Medicine study has concluded that there could be a significant impact on cognitive ...

Q4 2024 Earnings Call Transcript February 10, 2025 Vertex Pharmaceuticals Incorporated misses on earnings expectations. Reported EPS is $3.98 EPS, expectations were $4.02. Operator: Good day, and ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy ...

Given the remarkable advances seen with gene therapies for sickle ... disease areas, particularly SCD. One has been the move beyond simple transfusion to red blood cell exchanges (RBCX). If a ...

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.02 per share, down from $4.20 per share in the year-ago period. Vertex Pharmaceuticals projects quarterly ...